Diarrhoea (grade 2+) · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer
Summary of findings: Diet interventions showed no clear difference in diarrhoea (grade 2+) compared with usual on‐treatment diet (low certainty).
1 finding from 1 review
QoL · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer
Summary of findings: Diet interventions showed no clear difference in QOL scores (IBDQ) (higher scores better) compared with usual on‐treatment diet (low certainty).
3 findings from 1 review
MD 4.6
1 study · 50 participants
Low
no estimate extracted
1 study · 119 participants
GRADE not reported
MD 2.4
1 study · 76 participants
Low
Lactose‐restricted diet · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Diarrhoea (grade 1+) · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer
Summary of findings: Diet interventions showed no clear difference in diarrhoea (grade 1+) compared with usual on‐treatment diet (low certainty).
1 finding from 1 review
High‐fibre diet · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Low‐fibre diet · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Low‐fat diet · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean GI symptom scores (Vaizey scale) (higher scores better) · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer
Summary of findings: Diet interventions showed no clear difference in mean GI symptom scores (Vaizey scale) (higher scores better) compared with usual on‐treatment diet (low certainty).
1 finding from 1 review
Diarrhoea · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Prebiotic diet · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Absence of nausea ( · people with chemotherapy‐induced nausea and vomiting
Cannabinoids showed no clear difference in absence of nausea ( compared with placebo (low certainty).
1 finding from 1 review
Participant preference · people with chemotherapy‐induced nausea and vomiting
Cannabinoids may leads to higher participant preference ( compared with other anti‐emetic agent (low certainty).
1 finding from 1 review
Withdrawal for any reason (medium term: treatment duration from 5 to 8 weeks) · people with chemotherapy‐induced nausea and vomiting
Cannabinoids may leads to higher withdrawal any reason ( compared with other anti‐emetic agent (low certainty).
1 finding from 1 review
Lack of efficacy withdrawal · people with chemotherapy‐induced nausea and vomiting
It is very uncertain whether cannabinoids changes withdrawal due to lack of efficacy ( compared with other anti‐emetic agent (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with chemotherapy‐induced nausea and vomiting
Cannabinoids may leads to higher withdrawal due to adverse event ( compared with other anti‐emetic agent (low certainty).
1 finding from 1 review
Absence of vomiting ( · people with chemotherapy‐induced nausea and vomiting
Cannabinoids may leads to higher absence of vomiting ( compared with placebo (low certainty).
1 finding from 1 review
Absence of nausea and vomiting ( · people with chemotherapy‐induced nausea and vomiting
Cannabinoids probably leads to higher absence of nausea and vomiting ( compared with placebo (moderate certainty).
1 finding from 1 review
Participant preference · people with chemotherapy‐induced nausea and vomiting
Cannabinoids may leads to higher participant preference ( compared with placebo (low certainty).
1 finding from 1 review
Withdrawal for any reason (medium term: treatment duration from 5 to 8 weeks) · people with chemotherapy‐induced nausea and vomiting
It is very uncertain whether cannabinoids changes withdrawal any reason ( compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with chemotherapy‐induced nausea and vomiting
It is very uncertain whether cannabinoids changes withdrawal due to adverse event ( compared with placebo (very low certainty).
1 finding from 1 review